10 documents found, page 1 of 1

Sort by Issue Date

Complex Long-Term Catatonia

Rema, JP; Cavaco, T; Ferreira, D; Pereira, JM

Date: 2023   |   Origin: Hospital de Cascais

Pulmonary hyalinizing granuloma: Atypical presentation

Cunha, D; Melo, N; Guimarães, S; Moura, CS; Pereira, JM; Morais, A


Panton-Valentine Leukocidin-Producing Staphylococcus aureus Infection: A Case S...

Prista-Leão, B; Abreu, I; Duro, R; Silva-Pinto, A; Ceia, F; Andrade, P; Sobrinho-Simões, J; Tavares, M; Pereira, JM; Santos, L; Sarmento, A

Panton-Valentine leukocidin-producing Staphylococcus aureus (PVL-SA) is associated with relapsing multifocal skin and soft tissue infections (SSTI), necrotizing pneumonia (NP) and severe musculoskeletal infections. Epidemiology is underknown and underdiagnosis is likely. Recent travel abroad, case clustering and relapsing disease are often reported. We reviewed all cases of PVL-SA infection diagnosed at our cen...


Early prediction of treatment failure in severe community-acquired pneumonia: T...

Pereira, JM; Laszczyńska, O; Azevedo, A; Basílio, C; Sousa-Dias, C; Mergulhão, P; Paiva, JA

Purpose To identify a single/panel of biomarkers and to provide a point score that, after 48 h of treatment, could early predict treatment failure at fifth day of Intensive Care Unit (ICU) stay in severe community-acquired pneumonia (SCAP) patients. Materials and methods Single-center, prospective cohort study of 107 ICU patients with SCAP. Primary outcome included death or absence of improvement in Sequential ...


Impact of antibiotic therapy in severe community-acquired pneumonia: Data from ...

Pereira, JM; Gonçalves-Pereira, J; Ribeiro, O; Baptista, JP; Froes, F; Paiva, JA

Antibiotic therapy (AT) is the cornerstone of the management of severe community-acquired pneumonia (CAP). However, the best treatment strategy is far from being established. To evaluate the impact of different aspects of AT on the outcome of critically ill patients with CAP, we performed a post hoc analysis of all CAP patients enrolled in a prospective, observational, multicentre study. Of the 502 patients inc...


Mid-regional proadrenomedullin: An early marker of response in critically ill p...

Pereira, JM; Azevedo, A; Basilio, C; Sousa-Dias, C; Mergulhao, P; Paiva, JA

BACKGROUND:Mid-regional proadrenomedullin (MR-proADM) is a novel biomarker with potential prognostic utility in patients with community-acquired pneumonia (CAP). PURPOSE:To evaluate the value of MR-proADM levels at ICU admission for further severity stratification and outcome prediction, and its kinetics as an early predictor of response in severe CAP (SCAP). MATERIALS AND METHODS:Prospective, single-center, co...


Neuromyelitis optica spectrum disorder and varicella-zoster infection

Machado, C; Amorim, J; Rocha, J; Pereira, JM; Lourenço, E; Pinho, J


Early disrupted neurovascular coupling and changed event level hemodynamic resp...

Duarte, JV; Pereira, JM; Quendera, B; Raimundo, M; Moreno, C; Gomes, L; Carrilho, F; Castelo-Branco, M

Type 2 diabetes (T2DM) patients develop vascular complications and have increased risk for neurophysiological impairment. Vascular pathophysiology may alter the blood flow regulation in cerebral microvasculature, affecting neurovascular coupling. Reduced fMRI signal can result from decreased neuronal activation or disrupted neurovascular coupling. The uncertainty about pathophysiological mechanisms (neurodegene...


Carcinoma in situ and early breast carcinoma survey of the Portuguese Senology ...

Oliveira, CF; Rodrigues, V; Gervásio, H; Pereira, JM; Albano, J; Amaral, N

By means of a questionnaire sent to Portuguese hospitals which diagnose and treat most female patients with breast cancer, it was intended to assess the situation regarding the treatment of carcinoma in situ and early breast cancer (T1 or T2, N0 or N1), as well as their evolution between 1985 and 2000. The hospital participation rate was 65% and a sample of 865 patients was collected, distributed by the years 1...


Production and characterization of a mouse monoclonal antibody against the Gag ...

Marcelino, JM; Novo, C; Pereira, JM; Picotez, F; Clemente, A; Taveira, N

One anticapsid (p26) mouse monoclonal antibody was developed after immunization with recombinant p26 Gag protein and was tested for reactivity with different HIV-1 and HIV-2 isolates by ELISA and Western blot analysis. This antibody, named R26.1, reacted


10 Results

Queried text

Refine Results

Author





















Date










Document Type



Access rights




Resource







Subject